-
Trading On ThermoGenesis Shares To Resume At 9:45 AM
Friday, March 4, 2011 - 10:42am | 35Shares of ThermoGenesis Corp. (NASDAQ: KOOL) are currently halted and will begin trading again at 9:45AM. A secondary offering was priced at $2/share this morning.
-
ThermoGenesis Announces Pricing of Offering
Friday, March 4, 2011 - 10:03am | 89ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that it has determined the pricing for an offering of shares and warrants. The Company intends to sell 2,250,000 shares of common stock at $2.00 per share...
-
J.P. Morgan To Adjust Ratings For NuVasive Following 4Q10 Results
Friday, March 4, 2011 - 9:51am | 159In a report published by J.P. Morgan, NuVasive's (NASDAQ: NUVA) 2011 estimates are to be adjusted following its 4Q10 results. J.P. Morgan said that, for 2011 it now expects adjusted EPS of $1.10 (-25.5%) on total revenues of $536.2M (+12.1%). “Both of these estimates lie at the high end of...
-
Piper Jaffray Maintains Neutral Rating On BDX
Friday, March 4, 2011 - 9:03am | 141Given the recent Middle East turmoil and the resulting volatility in oil prices, “we felt an analysis of Becton, Dickinson and Company's (NYSE: BDX) exposure to oil prices was a prudent exercise,” Piper Jaffray reports. “As a reminder, BD utilizes oil-based resins as an input in multiple products...
-
Piper Jaffray Reiterating Overweight On DexCom (DXCM)
Friday, March 4, 2011 - 8:49am | 154Piper Jaffray is reiterating its Overweight rating on shares of DexCom, Inc. (NASDAQ: DXCM) and $16 price target. In a note to clients, Piper Jaffray writes, "DXCM Q4 product revenues of $13.6M, in line with the January pre-release, wereup 26% sequentially. Total revenue of $15.6M compared to our...
-
IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter
Thursday, March 3, 2011 - 5:18pm | 166IRIDEX Corporation (Nasdaq: IRIX) today reported that growing demand for new products and consumables drove sales and improved financial results for the fourth quarter ended January 1, 2011. Diluted earnings increased 62% to $0.8 million or $0.08 per share, up from $0.5 million or $0.05 per diluted...
-
DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results
Thursday, March 3, 2011 - 5:07pm | 208DexCom, Inc. (Nasdaq: DXCM) today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2010. For the full-year ended December 31, 2010, product revenue grew to $40.2 million, an increase of 123% from the $18.0 million in product revenue reported for...
-
J.P. Morgan Comments On Hansen Medical's Model Update
Thursday, March 3, 2011 - 11:33am | 197In a report published by J.P. Morgan, Hansen Medical (NASDAQ: HNSN) it is adjusting its Hansen estimates to take into account the company's recent 4Q10 results. J.P. Morgan said that, for 2011, it expects total revenues of $23.1M (+39%), down from $27.0M previously on more conservative system...
-
Active Screen - CANSLIM: Top 8 for March 3rd
Thursday, March 3, 2011 - 9:58am | 1280There was another shuffle in the lineup of the top-8 stocks ranked by Market Cap. Gone was Southwestern Energy (SWN) and in came Vale S.A. (VALE). The current top 8 are: Apple (AAPL), Vale S.A. (VALE), Barrick Gold (ABX), Free McMoran (FCX), Baidu (BIDU), Research in Motion (RIMM), Cognizant...
-
Piper Jaffray Reports Solid FQ3 Results For Cyberonics
Thursday, March 3, 2011 - 9:43am | 103In a report published by Piper Jaffray, Cyberonics (NASDAQ: CYBX) saw solid FQ3 results. Piper Jaffray said that CYBX reported FQ3 (January) results slightly ahead of expectation; Q4 guidance was essentially inline. “US revenues were up an impressive 24% including 13% new patient...
-
Goldman Sachs Has Buy On Hologic (HOLX)
Thursday, March 3, 2011 - 8:36am | 163Goldman Sachs has a Buy rating and a $25 price target on shares of Hologic, Inc. (NASDAQ: HOLX). In a note to investors, Goldman writes, "We are adding shares of Buy-rated Hologic to the Americas Conviction list, with 25% upside to our unchanged 6-month price target of $25. We...
-
Goldman Sachs Comments On Healthcare Sector (HOLX, UTHR)
Thursday, March 3, 2011 - 8:25am | 172Hologic (NASDAQ: HOLX) is well positioned to deliver upside to Street estimates owing to underappreciated upside from a pending product cycle in next generation digital mammography technology, known as tomosynthesis. Additionally, Goldman Sachs believes HOLX's strong FCF generation can support debt...
-
Meridian Bioscience Receives FDA Clearance For New illumigene C. difficile Pediatric Claim
Wednesday, March 2, 2011 - 4:00pm | 135Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new pediatric claim for its illumigene C. difficile (Clostridium difficile) molecular amplification test. C. difficile is a bacterium...
-
J.P. Morgan To Reduce Estimates And Maintain Neutral Rating For Mako Surgical
Wednesday, March 2, 2011 - 9:34am | 106According to J.P. Morgan, Mako Surgical (NASDAQ: MAKO) is reducing its estimates. J.P. Morgan reported that, following 4Q results, it is updating its Mako model and maintaining the Neutral rating. “Mako reported 4Q10 results that were in line with the company's previously announced metrics,...
-
Analogic Expects Solid Q2F11 Results on Medical Recovery, Says Benchmark
Wednesday, March 2, 2011 - 9:12am | 120According to Benchmark, Analogic Corporation (NASDAQ: ALOG) expects solid Q2F11 results on medical recovery. Benchmark reported that it expects a good quarter on continued medical recovery and steady security. “Analogic is scheduled to report its Q2FY11 results on Thursday, March 10th, after the...